Specific P2X7R antagonism in tauopathy models has been shown to reduce the accumulation of tau deposits [85], tau phosphorylation, and tau-induced toxicity [23], indicating that P2X7R antagonism is a potential therapeutic target for AD. The gene discussed is MAPT; the disease is tauopathy.